What do patients think of doctors?

Above is an animated presentation about PatientView’s latest report (optimised for Internet Explorer only). Please click on the forward arrow. The Prezi may take 30 seconds to load, so please be patient. Once loaded, to view in fullscreen, click on ‘More’.

                           A global survey of 2,500 patient groups

The report looks at virtually every aspect of doctor-patient relationships (including the role that pharma can play in improving those relationships):     ·          Improvements in access to health professionals requested by patients; ·         Improving the patient information provided by health professionals; ·         How patients would like doctor-patient communication improved; ·         Access and choice during diagnosis and treatment—improvements needed by patients (including a question about the desirable goals of treatment); ·         How health professionals can gain patient trust; ·         How health professionals can respect patients’ valuable time; ·         How health professionals can be made more accountable (both inside and outside the consulting room); ·         How health professionals might improve their prevention practices; ·         What single action do patients want from government and payers to improve doctor-patient relationships?; ·         Which pharma companies have a positive record on helping to improve doctor-patient relationships, and why?; ·         Why pharma can have a negative impact on doctor-patient relationships.

 The report contains thousands of quotations (arranged by country and by disease) from the 2,500 respondent patient groups.

Doctor-patient relations analysed for the following 12 countries and 12 disease areas: Australia [number of completed responses = 60]; Canada [138]; Eastern Europe [105]; France [80]; Germany [100]; Italy [110]; the Netherlands [30]; New Zealand [55]; Spain [80]; Sweden [56]; the UK [566]; and the USA [292].Cancer [160]; diabetes [55]; gastro-intestinal [40]; heart and circulatory conditions [70]; HIV/AIDS [72]; mental health [170]; multiple sclerosis [35]; neurological [195]; Parkinson’s disease [30]; rare diseases [70]; respiratory [35]; and rheumatological conditions [55].

Companies mentioned at least once by respondents: Abbott / Abbott Diagnostic / Abbott Italia / Actelion Pharmeuticals France / Alcon / Allergan / Amgen / Arthotec / Astellas / AstraZeneca / Baxter / Baxter Healthcare / Bayer / Bayer Schering / Berlin Chemie / Betapharm / Beximco Pharmaceutical Ltd/Bangladesh / Biogen Idec / Boehringer Ingelheim / Bristol Myers Squibb / Celgene / Centocor / Clinuvel / CT Arzneimittel / CT Medicines / Cyberonics Europe / Da Vinci Robotic Surgery System / Desitin / Efalex / Eli Lilly / Esparma / Ferring Pharmaceuticals / Gilead / GSK / Ipsen / Janssen Cilag / Janssen Ortho / Juvela / LEM (Les Entreprise du Médicament) / Leo Pharma / Lifescan Italia / London Drug Co in BC / Lundbeck / Medel / Medtronic / Menarini/ Merck / Merck Serono / MSD / Novartis / Novartis Oncology /Novo Nordisk / Nycomed / Ortho McNeil / Permamed / Pfizer / Pharmacy Guild of Australia / Q-pharma / Roche / Roche Diagnostics / Sanofi Aventis / Schering Plough / Servier / Solvay / St Jude / Storz / Stryker / Takeda / Talecris Biotherapeutics/ Temmler / Teva / Teva / Tibotec / UCB Pharma/ Vifor / Worwag Pharma

Profiling patient groups: The report concludes with a 109-page listing of the profiles of the respondent patient groups from around the world that wished to be named as survey participants.

To find out more about this report: Please email Alexandra Wyke or Clive Nead oninfo@patient-view.com